Colon cancer: new drug options improve on 5-FU.
J
J
McCann
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000069287:Capecitabine; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D005472:Fluorouracil / Q000627:therapeutic use; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D000077146:Irinotecan; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D011799:Quinazolines / Q000627:therapeutic use; D016019:Survival Analysis; D005641:Tegafur / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors; D059004:Topoisomerase I Inhibitors; D019772:Topotecan / Q000627:therapeutic use; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D009944:Organoplatinum Compounds; D011799:Quinazolines; D013876:Thiophenes; D059004:Topoisomerase I Inhibitors; D000077150:Oxaliplatin; D003841:Deoxycytidine; D005641:Tegafur; D000069287:Capecitabine; D000077146:Irinotecan; D019772:Topotecan; D013940:Thymidylate Synthase; C068874:raltitrexed; D005472:Fluorouracil; D002166:Camptothecin